Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
NCT07135050
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Pitt Hopkins Syndrome
Interventions
GENETIC:
MZ-1866
Sponsor
Mahzi Therapeutics
Collaborators
[object Object]